In a Phase II study, patients with HCC and macrovascular invasion experienced a 38.0% improvement in ORR after radiotherapy with a PD-1 monoclonal antibody compared to radiotherapy alone (31). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.